Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.84 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.66 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.66 |
| ▸ | MET | P08581 | 15/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15262000 | 0.99 | AXL (0.85) | AXLEHMT2EHMT1MET | |
| SCHEMBL698905 | 0.93 | AXL (0.84) | AXLMET | |
| SCHEMBL30000966 | 0.91 | AXL (1.00) | AXLMET | |
| SCHEMBL166239 | 0.91 | AXL (1.00) | AXLMET | |
| SCHEMBL14289180 | 0.91 | AXL (1.00) | AXLMET | |
| SCHEMBL1591237 | 0.90 | AXL (0.80) | AXLMET | |
| SCHEMBL1556008 | 0.89 | AXL (0.72) | AXLEHMT2EHMT1MET | |
| SCHEMBL16207509 | 0.88 | AXL (0.65) | AXLEHMT2EHMT1MET | |
| SCHEMBL20216817 | 0.88 | AXL (0.73) | AXLMET | |
| SCHEMBL15084599 | 0.87 | ABCB11 (0.67) | AXLEHMT2EHMT1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | claimed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | claimed |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-11-01 | — | — | US | claimed |
| EP-2462117-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-06-13 | — | — | EP | claimed |
| WO-2011045084-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-04-21 | — | — | WO | claimed |
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2462117-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-06-13 | — | — | EP | disclosed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | AXL 4326/4885EHMT2 2606/4885EHMT1 2450/4885 |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | AXL 4326/4885EHMT2 2606/4885EHMT1 2450/4885 |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | AXL 304/4885EHMT2 4588/4885EHMT1 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.